Giovanna Garufi, Luca Mastrantoni, Noemi Maliziola, Elena Di Monte, Giorgia Arcuri, Valentina Frescura, Angelachiara Rotondi, Alessandra Fabi, Ida Paris, Fabio Marazzi, Antonio Franco, Gianluca Franceschini, Antonella Palazzo, Armando Orlandi, Giovanni Scambia, Giampaolo Tortora, Carbognin Luisa, Emilio Bria
{"title":"根据HER2评分（低与0分），新辅助化疗在发光-HER2阴性早期乳腺癌中的活性和疗效：一项回顾性研究","authors":"Giovanna Garufi, Luca Mastrantoni, Noemi Maliziola, Elena Di Monte, Giorgia Arcuri, Valentina Frescura, Angelachiara Rotondi, Alessandra Fabi, Ida Paris, Fabio Marazzi, Antonio Franco, Gianluca Franceschini, Antonella Palazzo, Armando Orlandi, Giovanni Scambia, Giampaolo Tortora, Carbognin Luisa, Emilio Bria","doi":"10.1016/j.clbc.2025.02.016","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The predictive and prognostic role of HER2 status in patients with luminal-HER2 negative early breast cancer (BC) undergoing neoadjuvant chemotherapy is unclear. A retrospective analysis evaluating the correlation between HER2 status (low vs. score 0) and pCR/IDFS was conducted.</p><p><strong>Methods: </strong>Patients with BC undergoing neoadjuvant chemotherapy and surgery were included. HER2 low BC was defined as IHC 1+ or 2+ with negative FISH. Logistic regression model and Cox proportional hazard model were adopted to investigate the independent role of HER2 status and outcomes of interest (pCR, CPS-EG and IDFS).</p><p><strong>Results: </strong>About 566 patients were included: 60% were HER2 low and 40% were HER2 0. pCR was achieved in 13.2% of HER2 low versus 17.7% of HER2 0 (P = .15). There was no correlation between baseline HER2 status and CPS-EG score (P = .18). A trend toward improved IDFS for HER2 low BC was observed (P = .07). The relapse rate of the HER2 0 cohort peaked at 12 months after surgery, similar to the HER2 low cohort, which showed an additional peak at 36 months after surgery.</p><p><strong>Conclusions: </strong>Among Luminal-HER2 negative early BCs, our results do not support a clear predictive and prognostic effect of HER2 status, although a trend of worse pCR and better survival for HER2 low BCs cannot be ruled out.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study.\",\"authors\":\"Giovanna Garufi, Luca Mastrantoni, Noemi Maliziola, Elena Di Monte, Giorgia Arcuri, Valentina Frescura, Angelachiara Rotondi, Alessandra Fabi, Ida Paris, Fabio Marazzi, Antonio Franco, Gianluca Franceschini, Antonella Palazzo, Armando Orlandi, Giovanni Scambia, Giampaolo Tortora, Carbognin Luisa, Emilio Bria\",\"doi\":\"10.1016/j.clbc.2025.02.016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The predictive and prognostic role of HER2 status in patients with luminal-HER2 negative early breast cancer (BC) undergoing neoadjuvant chemotherapy is unclear. A retrospective analysis evaluating the correlation between HER2 status (low vs. score 0) and pCR/IDFS was conducted.</p><p><strong>Methods: </strong>Patients with BC undergoing neoadjuvant chemotherapy and surgery were included. HER2 low BC was defined as IHC 1+ or 2+ with negative FISH. Logistic regression model and Cox proportional hazard model were adopted to investigate the independent role of HER2 status and outcomes of interest (pCR, CPS-EG and IDFS).</p><p><strong>Results: </strong>About 566 patients were included: 60% were HER2 low and 40% were HER2 0. pCR was achieved in 13.2% of HER2 low versus 17.7% of HER2 0 (P = .15). There was no correlation between baseline HER2 status and CPS-EG score (P = .18). A trend toward improved IDFS for HER2 low BC was observed (P = .07). The relapse rate of the HER2 0 cohort peaked at 12 months after surgery, similar to the HER2 low cohort, which showed an additional peak at 36 months after surgery.</p><p><strong>Conclusions: </strong>Among Luminal-HER2 negative early BCs, our results do not support a clear predictive and prognostic effect of HER2 status, although a trend of worse pCR and better survival for HER2 low BCs cannot be ruled out.</p>\",\"PeriodicalId\":10197,\"journal\":{\"name\":\"Clinical breast cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-03-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical breast cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.clbc.2025.02.016\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clbc.2025.02.016","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study.
Background: The predictive and prognostic role of HER2 status in patients with luminal-HER2 negative early breast cancer (BC) undergoing neoadjuvant chemotherapy is unclear. A retrospective analysis evaluating the correlation between HER2 status (low vs. score 0) and pCR/IDFS was conducted.
Methods: Patients with BC undergoing neoadjuvant chemotherapy and surgery were included. HER2 low BC was defined as IHC 1+ or 2+ with negative FISH. Logistic regression model and Cox proportional hazard model were adopted to investigate the independent role of HER2 status and outcomes of interest (pCR, CPS-EG and IDFS).
Results: About 566 patients were included: 60% were HER2 low and 40% were HER2 0. pCR was achieved in 13.2% of HER2 low versus 17.7% of HER2 0 (P = .15). There was no correlation between baseline HER2 status and CPS-EG score (P = .18). A trend toward improved IDFS for HER2 low BC was observed (P = .07). The relapse rate of the HER2 0 cohort peaked at 12 months after surgery, similar to the HER2 low cohort, which showed an additional peak at 36 months after surgery.
Conclusions: Among Luminal-HER2 negative early BCs, our results do not support a clear predictive and prognostic effect of HER2 status, although a trend of worse pCR and better survival for HER2 low BCs cannot be ruled out.
期刊介绍：
Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
